CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
了解继发于内在性或医源性免疫失调的中性粒细胞减少症
英文原题：Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation.
查看英文原题
Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
作为固有免疫和适应性免疫应答的关键成员，中性粒细胞为理解先天性免疫缺陷（IEI）的血液学和炎症表现以及免疫治疗的后果提供了重要视角。以中性粒细胞减少症为表现的IEI易于识别，这为血液科医生提供了促进早期诊断和加快生物学合理治疗的途径。此外，加深对IEI中驱动中性粒细胞减少的分子机制——骨髓储备减少、骨髓释放减少和存活期缩短——的理解，为进一步剖析继发于医源性免疫失调（如免疫检查点抑制剂和CAR-T 细胞治疗）的中性粒细胞减少的病理生理机制提供了机会。
展开英文摘要原文
As a key member of the innate and adaptive immune response, neutrophils provide insights into the hematopoietic and inflammatory manifestations of inborn errors of immunity (IEI) and the consequences of immunotherapy. The facile recognition of IEI presenting with neutropenia provides an avenue for hematologists to facilitate early diagnosis and expedite biologically rationale care.
Moreover, enhancing the understanding of the molecular mechanisms driving neutropenia in IEI-decreased bone marrow reserves, diminished egress from the bone marrow, and decreased survival-offers an opportunity to further dissect the pathophysiology driving neutropenia secondary to iatrogenic immune dysregulation, eg, immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
论文信息
- 作者
- Walkovich K、Connelly JA
- 第一作者单位
- Department of Pediatrics, University of Michigan, Ann Arbor, MI.United States
- 通讯作者单位
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.United States
- 文献类型
- 病例报告
- 期刊
- Hematology. American Society of Hematology. Education Program2021 Dec 10
- 原文标识
- PubMed 34889406 · DOI 10.1182/hematology.2021000285
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →